Célia Maria Camelo Silva

Dr. Célia Maria Camelo Silva

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2022 in Jornal de Pediatria
Verified
Journal Article
Open access
FCFernanda Souza Angotti Carrara
Fernanda Souza Angotti Carrara
DPDaniela Gerent Petry Piotto
Daniela Gerent Petry Piotto
ISIlana Izidoro Silva
Ilana Izidoro Silva
CLClaudio Arnaldo Len
Claudio Arnaldo Len
GRGleice Clemente Souza Russo
Gleice Clemente Souza Russo
MTMaria Teresa Terreri
Maria Teresa Terreri
Advances in medicine have increased the life expectancy of pediatric patients with chronic illnesses, and challenges with the guided transition of adolescents and young adults from pediatric clinics to adult clinics have grown. The aim of this study was to better understand readiness and factors related to this transition process in Brazil. In this cross-sectional study of 308 patients aged from 16 to 21 years under follow-up in pediatric specialties, the degree of readiness for transition was assessed using the Transition Readiness Assessment Questionnaire (TRAQ) and its domains. Associations with demographic data, clinical data, socio-economic level, medication adherence, family functionality, and parental satisfaction with health care were evaluated. The median TRAQ score was 3.7 (3.2 – 4.2). Better readiness was associated with female patients, socio-economic class A-B, current active employment, higher level of education, not failing any school year, attending medical appointments alone, functional family, and a good knowledge of disease and medications. A low correlation was observed between TRAQ and age. TRAQ presented good internal consistency (alpha-Cronbach 0.86). In the multiple linear regression, TRAQ score showed a significant association with female gender, advanced age, socio-economic class A-B, better knowledge of disease and medications, and independence to attend appointments alone. TRAQ instrument can guide healthcare professionals to identify specific areas of approach, in order to support adolescents with chronic disease to set goals for their own personal development and improve their readiness to enter into the adult healthcare system. In this study, some factors were related to better TRAQ scores.

16 October 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
FTFernando Sabia TALLO
Fernando Sabia TALLO
PSPatricia Oliveira de Santana
Patricia Oliveira de Santana
Sandra Augusta Gordinho PintoSandra Augusta Gordinho Pinto
Sandra Augusta Gordinho Pinto
RLRildo Yamaguti Lima
Rildo Yamaguti Lima
Erisvaldo Amarante Amarante de AraújoErisvaldo Amarante Amarante de Araújo
Erisvaldo Amarante Amarante de Araújo
FMFrancisco Sandro Menezes-Rodrigues
Francisco Sandro Menezes-Rodrigues
Acute myocardial infarction (AMI) is the main cause of morbidity and mortality worldwide and is characterized by severe and fatal arrhythmias induced by cardiac ischemia/reperfusion (CIR). However, the molecular mechanisms involved in these arrhythmias are still little understood. To investigate the cardioprotective role of the cardiac Ca2+/cAMP/adenosine signaling pathway in AMI, L-type Ca2+ channels (LTCC) were blocked with either nifedipine (NIF) or verapamil (VER), with or without A1-adenosine (ADO), receptors (A1R), antagonist (DPCPX), or cAMP efflux blocker probenecid (PROB), and the incidence of ventricular arrhythmias (VA), atrioventricular block (AVB), and lethality (LET) induced by CIR in rats was evaluated. VA, AVB and LET incidences were evaluated by ECG analysis and compared between control (CIR group) and intravenously treated 5 min before CIR with NIF 1, 10, and 30 mg/kg and VER 1 mg/kg in the presence or absence of PROB 100 mg/kg or DPCPX 100 µg/kg. The serum levels of cardiac injury biomarkers total creatine kinase (CK) and CK-MB were quantified. Both NIF and VER treatment were able to attenuate cardiac arrhythmias caused by CIR; however, these antiarrhythmic effects were abolished by pretreatment with PROB and DPCPX. The total serum CK and CK-MB were similar in all groups. These results indicate that the pharmacological modulation of Ca2+/cAMP/ADO in cardiac cells by means of attenuation of Ca2+ influx via LTCC and the activation of A1R by endogenous ADO could be a promising therapeutic strategy to reduce the incidence of severe and fatal arrhythmias caused by AMI in humans.
1

Verified
Journal Article
Open access
PDF file
FMFrancisco Sandro Menezes-Rodrigues
Francisco Sandro Menezes-Rodrigues
ECElisa Andrade Costa
Elisa Andrade Costa
PMPedro Ivo De Marqui Moraes
Pedro Ivo De Marqui Moraes
Erisvaldo Amarante Amarante de AraújoErisvaldo Amarante Amarante de Araújo
Erisvaldo Amarante Amarante de Araújo
CFCarlos Eduardo Braga Filho
Carlos Eduardo Braga Filho
FTFernando Sabia Tallo
Fernando Sabia Tallo
The most common cause of morbidity and death worldwide is acute myocardial infarction (AMI), which is typified by severe and deadly arrhythmias resulting from cardiac ischemia and reperfusion (CIR). We chose to investigate the possible cardioprotective activity of epiisopiloturine (EPI), an imidazole alkaloid presents in the leaves of Pilocarpus microphyllus, in an animal model of CIR in rats. Control rats were treated with 0.9% saline solution and then subjected to CIR (SS + CIR); they were compared to rats pretreated with either 10 mg/kg (EPI10 + CIR group) or 15 mg/kg EPI (EPI15 + CIR) before CIR. ECG analysis was used to assess the incidence of ventricular arrhythmias (VAs), atrioventricular block (AVB), and lethality (LET) brought on by CIR in these rats. Serum creatine kinase-MB (CK-MB) was assessed using a colorimetric assay. In comparison to the SS + CIR group, animals treated with EPI15 + CIR had lower AVB incidence, which decreased from 85.7% to 21.4%, while LET incidence decreased from 71.4% to 21.4%. In both EPI10 + CIR and EPI15 + CIR groups, serum CK-MB was lower than in SS + CIR positive controls. These findings suggest that administration of EPI (15 mg/kg) before CIR could reduce the incidences of AVB and LET, as well as cardiac injury markers, which suggests that, likely due to its antioxidant effects, EPI may be a promising drug to reduce LET in patients with severe and fatal arrhythmia due to AMI.

1 January 2025 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
ASAdilson Costa dos Santos
Adilson Costa dos Santos
CSCélia Maria Camelo Silva
Célia Maria Camelo Silva
EAErisvaldo Amarante de Araújo
Erisvaldo Amarante de Araújo
LSLucas de Oliveira Sassi
Lucas de Oliveira Sassi
ACAdriano Caixeta
Adriano Caixeta
FMFrancisco Sandro Menezes-Rodrigues
Francisco Sandro Menezes-Rodrigues
SUMMARY OBJECTIVE: The aim of the study was to evaluate the cardiotoxic effects of pantoprazole in Wistar rats submitted to cardiac ischemia and reperfusion. METHODS: Cardiac ischemia and reperfusion was induced in rats through tourniquet of the left anterior descending coronary artery (10 min) followed by reperfusion (75 min). The incidences of ventricular arrhythmias, atrioventricular block, and lethality were evaluated by electrocardiogram analysis and compared between the control group (saline solution+cardiac ischemia and reperfusion) and the animals treated with pantoprazole 36 mg/kg (pantoprazole+cardiac ischemia and reperfusion), intravenously, immediately before cardiac ischemia (pantoprazole+cardiac ischemia and reperfusion) or before cardiac reperfusion (pantoprazole+cardiac reperfusion). RESULTS: There were no differences between the incidences of ventricular arrhythmias in the groups studied. Treatment with pantoprazole before cardiac ischemia and reperfusion increased the incidence of atrioventricular block and lethality and myocardial injuries compared to the saline solution+cardiac ischemia and reperfusion group, but treatment of animals with pantoprazole before cardiac reperfusion decreased these parameters and serum creatine kinase-MB levels. CONCLUSION: Our results indicate that when pantoprazole is administered before cardiac ischemia and reperfusion, it promotes cardiotoxicity; however, when administered before cardiac reperfusion, it promotes cardioprotection in Wistar rats.

20 September 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
FTFernando Sabia TALLO
Fernando Sabia TALLO
PSPatrícia Oliveira Santana
Patrícia Oliveira Santana
Sandra Augusta Gordinho PintoSandra Augusta Gordinho Pinto
Sandra Augusta Gordinho Pinto
RLRildo Yamaguti Lima
Rildo Yamaguti Lima
Erisvaldo Amarante Amarante de AraújoErisvaldo Amarante Amarante de Araújo
Erisvaldo Amarante Amarante de Araújo
FMFrancisco Sandro Menezes-Rodrigues
Francisco Sandro Menezes-Rodrigues
Characterized by severe and fatal arrhythmias induced by cardiac ischemia/reperfusion (CIR), acute myocardial infarction (AMI) is the main cause of morbidity and mortality worldwide. To investigate the cardioprotective role of cardiac Ca2+/cAMP/adenosine signaling in AMI, the effects of L-type Ca2+ channels (LTCC) blocker Nifedipine (NIF) and Verapamil (VER), in the absence and presence of A1-adenosine receptors (A1R) blocker (DPCPX), on the incidence of ventricular arrhythmias (VA), atrioventricular block (AVB) and lethality (LET) induced by CIR in rats were evaluated. CIR was induced in adult male Wistar rats (290-320 g) by occlusion of the left anterior descendent coronary artery (10 min) followed by reperfusion (75 min). VA, AVB and LET incidences were evaluated by ECG analysis and compared between control (CIR group) and intravenously treated 5 min before CIR with NIF 1, 10, and 30 mg/kg (NIF+CIR groups) or DPCPX 100 µg/kg plus NIF 10 mg/kg (DPCPX+NIF+CIR group) and VER 1 mg/kg (VER+CIR group) or DPCPX 100 µg/kg plus VER 1 mg/kg (DPCPX+VER+CIR group). Serum levels of cardiac injury biomarkers (TCK and CK-MB) were quantified. In CIR group, VA, AVB and LET incidences were 90, 80 and 70%, respectively. In NIF+CIR group, incidence of VA was reduced to 50, 30 and 30%, AVB to 25, 10 and 20%, and LET to 25, 20 and 20%, and respectively. In DPCPX+NIF+CIR group, these incidences were not different from CIR group. TCK and CK-MB levels were similar in all groups. These results indicate that pharmacological modulation of the Ca2+/cAMP/adenosine signaling in cardiac cells by LTCC blockade and A1R stimulation could be a new strategy cardioprotective for human AMI therapy.
1

1 January 2026 in Acta Cirurgica Brasileira
Verified
Journal Article
Open access
RLRildo Yamaguti Lima
Rildo Yamaguti Lima
TGTania Carmen Peñaranda Govato
Tania Carmen Peñaranda Govato
EAErisvaldo Amarante de Araújo
Erisvaldo Amarante de Araújo
MOMarcelo Pires de Oliveira
Marcelo Pires de Oliveira
PSPaulo Sérgio de Araujo Sousa
Paulo Sérgio de Araujo Sousa
FMFrancisco Sandro Menezes-Rodrigues
Francisco Sandro Menezes-Rodrigues
Purpose: Although methylene blue (MB) has long been used to treat vasoplegic syndrome, its pharmacodynamics and cardiovascular effects remain unclear. Therefore, we decided to evaluate the potential molecular targets of MB through molecular docking and its cardioprotective and antioxidant actions. Methods: Adult male spontaneously hypertensive rats (SHR) were allocated into four groups: sham-operated; treated with vehicle and subjected to cardiac ischemia and reperfusion (CIR) (SS+CIR); treated with 2 mg/kg of MB before cardiac ischemia and reperfusion (MB+ISQ); and treated with 2 mg/kg of MB before cardiac reperfusion (ISQ+MB). The animals were monitored with electrocardiogram to assess the incidence of ventricular arrhythmias (VA), atrioventricular blocks (AVB), and lethality (LET). Blood samples and hearts were collected for histopathological analysis, serum creatine kinase MB dosage, and measurement of lipid hydroperoxide (LH) in myocardium serum creatine kinase MB. Results: The incidences of AVB and LET, serum CK-MB concentration, and myocardial injury increased in the MB+ISQ group, but not in the ISQ+MB group when compared with the SS+CIR group. LH concentration decreased in both MB-treated groups when compared with the SS+CIR group. Conclusion: These results indicate that MB produces a cardiotoxic effect only when administered before CIR, but not when administered before cardiac reperfusion.